Host Immune Response Modulation

Host immune response modulation strategically enhances or suppresses immune function depending on therapeutic objectives. Immunotherapy augments anti-tumour immunity. Immunosuppression prevents allograft rejection. Tolerisation reduces autoimmune responses. Innate immunity activation via toll-like receptor agonists enhances immune engagement.

Biomarker assessment predicts immune response magnitude. Combination approaches enhance immune modulation. Regulatory submissions justify immune targeting rationale. Adverse event monitoring detects excessive immune activation. Post-approval surveillance identifies unexpected immune effects.